# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jefferies analyst Akash Tewari upgrades BioNTech (NASDAQ:BNTX) from Hold to Buy and raises the price target from $96 to $150.
Florida advises against mRNA Covid vaccines for vulnerable residents, citing safety concerns. Gov. DeSantis' administration...
JP Morgan analyst Jessica Fye upgrades BioNTech (NASDAQ:BNTX) from Underweight to Neutral and raises the price target from $...
B of A Securities analyst Tazeen Ahmad maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $125 to ...
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...
Jefferies analyst Akash Tewari maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $90 to $96.
https://www.nbcnews.com/health/health-news/florida-covid-shots-mrna-vaccines-older-adults-rcna170997Even as the Covid wave in F...